Clinical Trial: Non-Invasive Chromosomal Evaluation of 22q11.2
Study Status: Recruiting
Recruit Status: Recruiting
Study Type: Observational
Official Title: Non-Invasive Chromosomal Evaluation of 22q11.2 Using Cell-free Fetal DNA From Maternal Plasma
Brief Summary: This study is being conducted to develop and evaluate a cell-free fetal DNA test (Ariosa Test) for non-invasive prenatal detection of 22q11.2 chromosomal deletion or duplication. Investigators will be evaluating subjects with abnormal U/S.
Detailed Summary:
Sponsor: Roche Sequencing Solutions
Current Primary Outcome: Performance of Ariosa 22q.11.2 deletion/duplication assay in prenatal patients [ Time Frame: 18 months ]
Original Primary Outcome: Same as current
Current Secondary Outcome:
Original Secondary Outcome:
Information By: Roche Sequencing Solutions
Dates:
Date Received: September 2, 2015
Date Started: June 2015
Date Completion: December 2017
Last Updated: July 15, 2016
Last Verified: July 2016